An overview of the United States, European and Global medical technology industry with performance metrics and analysis of the context within which the industry operates. Demographic, regulatory, macro-economic and expanding non-traditional markets create a need for innovative approaches to developing better medical technologies going forward. Click to download >> Continue reading
From: The Members of the Arizona Bioscience Industry
RE: Proposed lowering of the ASP percentage from 6% to 4% could have dangerous side effects and information in support of the Lance/Pascrell letter that is being circulated.
We have a lot of things that need fixing at the moment as the financial burden our country bears comes under further review and adjustments. Many of our systems are broken, but some are working. ASP and Medicare Part B is a case in point.
In keeping with the Arizona BioIndustry Association’s commitment to monitor key issues and to share key information on areas that affect our community, our state and our nation, the following points are offered to assist you on how best to control healthcare costs and protect jobs while serving the best interests of millions of Americans and tens of thousands of Arizonans who are touched directly or indirectly by the current ASP rates and the Medicare Part B Program.
HISTORY/BACKGROUND: ASP and Biologics:
Biologics are used to treat some of the most serious diseases. Many of these products are infused directly into the patients’ blood stream and require administration in a physician’s office because of their complexity and the need to monitor how the patient is responding. Medicare pays for these products under Part B of the statute and pay for the product at the average sales price plus a physician add-on that covers the handling and administration of the product. This system was created as a replacement to the old system in order to better reflect the cost of the products. The change in the program is estimated to have saved $16 billion since the MMA was implemented in 2005.
ASP+6% is working well and there is no policy argument for reducing the add-on payment down to 3%. MedPac, which makes recommendations to Congress on CMS policy, has found that the 6% is an adequate payment level. The only reason to dial down the % is to save the government money, approximately $3 billion but is unlikely to be a true savings as these costs will reappear in other places.
Some providers, especially in rural areas, are already struggling. Many of these providers are small businesses that provide lifesaving medical services in their communities. Passing the cost burden to these small companies could result in curtailment of their service offerings in their communities. As services are cut back, jobs are lost.
Dialing down the percentage has the potential to really disrupt the delivery system, creating potential access problems for patients and ultimately costing the government more as these patients end up in the hospital for either the initial treatment or complications caused by limited access to these treatments and
services that land them in the hospital with more serious problems later.
In addition, the regulatory changes that would be needed to implement this change may face significant hurdles in implementation during the Regulatory Flexibility Review. As you know, The Regulatory Flexibility Act, which was created in 1980 and amended in 1996, requires federal agencies to assess the economic impact of proposed and existing regulations on small businesses. Rules found to be too burdensome must be replaced with alternatives. A government mandated profit margin that falls below the operating costs of these small businesses will effectively drive small business providers out of the market as they would not be able to sustain operations at this level or compete with large businesses that have other areas where they can shift costs to keep their operations solvent.
The 6% is not all profit for these providers. Within that they have to deal with numerous factors critical for their business model including the prompt pay discount, bad debt, handling and administration and others. Lowering the add-on will force certain providers to no longer take Medicare patients, forcing them into the hospital setting which is more expensive and less convenient.
This sort of disruption, to a system that is working, for a cost saving estimated at $3 billion over 10 years will have dangerous side effects for little to no real benefit. This is basically a rounding error in the larger healthcare cost and budget debate and once the unintended consequences to small businesses, jobs, and patient access are added in potentially a net increase healthcare costs and yet another hurdle for businesses of all sizes as we strive for economic recovery.
As I shared in the beginning, ASP and Medicare Part B is Working. It has allowed us to reduce healthcare costs and through the products it covers stimulate innovation and create jobs. The current 6% level offers a slim but manageable profit margin for small business providers. Fixing a system that is not
broken could negatively impact thousands of Arizonans and millions of Americans. I know you have a lot on your plate in solving the financial challenges our country is facing. Perhaps it is time to take changes to the ASP+6% Rate and Medicare Part B off the “fix it list” and use our scarce resources to address other challenges that can truly use the help.
On behalf of the Arizona BioIndustry and our community, I thank you for taking the time to read this letter and for doing what is best for all of us.
Sincerely,Joan Koerber-Walker President and CEO AZBio – The Arizona BioIndustry Association SkySong, 1475 N. Scottsdale Road, Scottsdale, AZ 85257
Arizona biosciences sector demonstrates how to accelerate innovation and job growth and offers insight on how Washington can keep things moving forward faster by activating its “collaborative gene.”
These days tales of economic vitality are few and far between making Arizona’s bioscience sector an inspiration to all as the nation focuses on jobs and economic recovery.
Thanks to a coordinated plan developed in 2002 and supported by leaders from Arizona’s healthcare industry, corporations, government, and universities that has been led by the Flinn Foundation with support from Battelle, Arizona is moving forward faster in economic development, job creation and bioscience research.Continue reading
The Arizona BioIndustry is Moving Forward Faster in 2011
The Arizona BioIndustry Association has selected finalists and honorees for its annual awards gala to be held at the Sheraton Wild Horse Pass on Oct. 13. Awards to be presented include: 2011 Michael A. Cusanovich Educator of the Year, Fast Lane Company Awards, the Arizona Bioscience Company of the Year, the Jon W. McGarity Bioscience Leader of the Year Award, and the Arizona Bioscience Researcher of the Year Award.
Patrick Soon-Shiong, chairman and CEO of National LambdaRail, announced the appointment of ASU President Michael M. Crow as head of a new Chairman’s Advisory Council.Aided by a $100 million guarantee from the Chan Soon-Shiong Institute for Advanced Health to upgrade and extend its network to support big science projects, the council will help guide the new mission of National LambdaRail, the 12,000-mile-high-performance communications network linking the nation’s leading research institutions.Continue reading
Regenesis Biomedical to Participate in the AdvaMed 2011 MedTech Conference: Selected to present in the Wound Management category and serve as a panelist on Emerging Growth Companies.
Scottsdale, Arizona, September 5, 2011 — Regenesis Biomedical, Inc., a medical technology company focused on regenerative medicine, announced today that it was selected to present at the AdvaMed 2011 MedTech conference. Regenesis presents in the Wound Management category. The aim of the conference is to connect companies that have an innovative medical technology to parties interested in investing capital, partnering, or initiating strategic alliances.Continue reading
09/11/2011 | Arizona Republic | Ken Alltucker
It’s two weeks before the new Banner MD Anderson Cancer Center opens for patients, but its new appointment calendar is filling quickly. The early interest has Banner Health CEO Peter Fine and his staff talking about plans to expand the facility, which is 133,000 square feet. But Fine acknowledges that metro Phoenix patients will be the ultimate judge of how quickly the center grows.
Gowan partners with Colombia company to promote ‘green’ products 09/09/2011 | Yuma Sun | Chris McDaniel
Gowan Company of Yuma has reached an agreement with EcoFlora, a company in Colombia, to create a joint venture called EcoFlora AGRO. Through this joint venture, Gowan Company and its global marketing companies will be the exclusive partner in developing, registering, and marketing EcoFlora’s current unique plant extract based portfolio and their robust product pipeline.
Executive profile: R.F. ‘Rick’ Shangraw Jr. of Arizona State University 09/09/2011 | Phoenix Business Journal | Patrick O’Grady
Rick Shangraw has seen technology and growth from both the public and private
sectors. Shangraw currently heads up Arizona State University’s Office of Knowledge Enterprise Development, which is designed to take the best of the university’s ideas and turn them into commercial realities.
UA-linked hospitals get new names 09/08/2011 | Arizona Daily Star | Stephanie Innes
University Medical Center is now called the University of Arizona Medical Center-University Campus. And University Physicians Healthcare Hospital at Kino will now be known as the University of Arizona Medical Center-South Campus. Both hospitals are part of the University of Arizona Health Network, which is the new name for the entity that formed in the summer of 2010 when University Medical Center Corp. merged with University Physicians Healthcare.
Phoenix OKs construction of $17 mil parking garage on Biomedical Campus 09/08/2011 | Downtown Devil | Jessica Zook
The City of Phoenix approved a proposal Wednesday for the construction of a $17 million parking garage downtown. The Boyer Company gained approval as the real-estate developer for the garage, which will serve the growing Phoenix Biomedical Campus and will be on the southeast corner of Fillmore and Fifth streets. Construction is scheduled to start in November 2012 and be complete by early February 2014.
Arizona has netted $2.6B in health-related stimulus since 2009
09/07/2011 | Business Journal | Angela Gonzales
Since the enactment of the American Recovery and Reinvestment Act of 2009, the U.S. Department of Health and Human Services has made $2.6 billion in stimulus funds available in Arizona. Of that, $2.2 billion went for the increased federal share of state Medicaid costs, while another $106 million went to scientific research, facilities and equipment.
Innovations make tech incubator live up to its name
(editorial) 09/07/2011 | Arizona Republic
The Innovations Technology Incubator is part of Chandler’s mission to create high-wage jobs for residents. The idea is to grow and foster ideas in science and technology. Once that happens, entrepreneurs would leave Innovations to buy or lease buildings, purchase equipment and create jobs in Chandler. Christine Mackay, Chandler’s economic-development director, says the city has been approached by new companies and existing tenants that need more space. The current facility is 100 percent occupied.
Regents panel OKs UA plans for 2 new research buildings 09/02/2011 | Arizona Daily Star | Becky Pallack
The University of Arizona is adding two new research buildings on the north side of Speedway to its wish list. Capital improvement plans were approved by an Arizona Board of Regents committee on Thursday. A proposed $85 million bioscience lab facility would be built near the Bio5 building for disease research.
ASU scientists receive $5 mil for DNA research 09/01/2011
| State Press | Kharli Mandeville
What if there was a way for doctors to know what diseases their patients were susceptible to before they even showed symptoms? Two Biodesign Institute researchers have been awarded more than $5 million in grants to further pursue research into a cutting edge technology to sequence an individual’s genetic information, or genome.
ERIC BETZ Sun Staff Reporter azdailysun.com | Monday, September 12, 2011
- On the morning of September 11, 2001, Paul Keim was out for a run with his dog on Observatory Mesa, oblivious to the events unfolding along the eastern seaboard.
He was training for a marathon that he would never run.
Within weeks, he would be sitting on the hood of his Toyota on the tarmac at Flagstaff Pulliam Airport when a blonde woman walked off a Gulfstream jet and handed him a package.
“Dr. Keim, this is the anthrax,” she told him. Read more at the Arizona Daily Sun
WASHINGTON,D.C. –The medical device tax, if implemented, could cost tens of thousands of jobs, almost double the industry’s total taxes, raise the effective tax rate to among the highest in the world, and harm U.S. competiveness, according to a study released today by the Advanced Medical Technology Association (AdvaMed). The new study, “Employment Effects of the New Excise Tax on the Medical Device Industry,” by Manhattan Institute senior fellow Diana Furchtgott-Roth and Hudson Institute senior fellow Harold Furchtgott-Roth, outlines a number of economic harms likely to result from the tax.Continue reading
ASU’s Leland Hartwell, Nobel laureate and chief scientist at the Biodesign Institute’s Center for Sustainable Health, spearheaded the agreement with Jianping Wang, director of the SYSU Gastrointestinal Institute of the Sixth Affiliated Hospital in Guangzhou, Guangdong, China.
ASU, China’s Sun Yat-Sen University partner
Arizona State University and China’s Sun Yat-Sen University (SYSU) have formalized a research collaboration aimed at developing early and predictive diagnostics to improve patient outcomes for colorectal cancer. ASU’s Leland Hartwell, Nobel laureate and chief scientist at the Biodesign Institute’s Center for Sustainable Health, spearheaded the agreement with Jianping Wang, director of the SYSU Gastrointestinal Institute of the Sixth Affiliated Hospital in Guangzhou, Guangdong, China.
“Recent advances in molecular technologies promise great improvements in medical care through prevention and early detection of disease,” Hartwell said.
Read more at ASU News